VA Palo Alto Health Care System
Palo Alto, California, 94089, United States
NCT Number: NCT02429778
The PI developed a self-directed program to treat late-life anxiety called Breathing, Relaxation, and Education for Anxiety Treatment in the Home Environment (BREATHE). This program consists of weekly video lessons that participants watch on digital video disc (DVD) along with weekly telephone check-ins. In BREATHE participants will learn two behavioral interventions: diaphragmatic breathing and progressive muscle relaxation (PMR). The purpose of the study is to examine whether the self-directed BREATHE program is superior to a wait list control in reducing anxiety in older adults with anxiety disorders. For those assigned to wait list control, they will be offered opportunity to participate in BREATHE treatment after 8 weeks of wait list.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Palo Alto, California, 94089, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Deep or diaphragmatic breathing is taught prior to relaxation.
Other names: Deep breathing
Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
Other names: Progressive Relaxation Training
Time frame: Change from baseline to 8 weeks
The Geriatric Anxiety Scale (GAS) is a 30-item measure of somatic, cognitive, and affective symptoms of anxiety. The first 25 items of the measure are used to compute the total score; the last 5 items provide information about the content of worries or fears. Total scores range from 0 to 75 with higher scores indicating worse anxiety. Participants provide severity ratings for items using on a four-point Likert-type scale.
Time frame: Change from baseline to 8 weeks
The Activity Card Sort contains 80 photographs that depict the performance of instrumental activities, low-physical-demand leisure activities, high-physical-demand leisure activities, and social activities. This measure will be used to assess engagement in activities. The score reported is the lifestyle-adjusted function score. It represents the percentage of activities ever completed that are perceived to be easy. Higher scores indicate greater ease of activity completion/engagement.
Time frame: Change from baseline to 8 weeks
The Patient Health Questionnaire 9-item (PHQ-9) is a 9-item depression assessment rated on a four-point Likert-type scale with scores ranging from 0 to 27. It includes one item that inquires about suicide ideation. Higher scores indicate more severe depressive symptoms. Validity and reliability have been established with primary care patients.
Time frame: Change from baseline to 8 weeks
Somatic Symptom Scale (SSS-8). The SSS-8 is an 8-item somatic symptom assessment rated on a five-point Likert-type scale with scores ranging from 0 to 32. The SSS-8 is administered to characterize participants' somatic symptoms. Higher symptoms indicate worse somatic symptom severity.
Time frame: Change from baseline to 8 weeks
Heart rate will be measured at baseline and at 8 weeks after enrollment. This is an exploratory measure.
Time frame: Change from baseline to 8 weeks
Blood pressure will be measured at baseline and at 8 weeks after enrollment. This is an exploratory measure.
Palo Alto Veterans Institute for Research
Other
Reducing Late-Life Anxiety and Improving Functioning With Self-Directed Relaxation
Acronym: BREATHE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03100279
Anxiety Disorders, Behavior
Piscataway, New Jersey, United States
View Trial DetailsNCT01829100
Anxiety Disorders, Depressive Disorder
Piscataway, New Jersey, United States
View Trial DetailsNCT06282146
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT05927987
Anxiety Disorders, Depressive Disorder
Amsterdam, Netherlands
View Trial Details